Nuveen’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Nuveen’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-511	Closed	-$10	–	1450
2016 Q1	$10	Sell	511 -25	-5%	-$481	﹤0.01%	1387
2015 Q4	$14	Sell	536 -20	-4%	-$695	﹤0.01%	1502
2015 Q3	$25	Sell	556 -52	-9%	-$1.96K	﹤0.01%	1528
2015 Q2	$20	Hold	608	–	–	﹤0.01%	1580
2015 Q1	$19K	Hold	608	–	–	﹤0.01%	1572
2014 Q4	$23K	Hold	608	–	–	﹤0.01%	1598
2014 Q3	$16K	Hold	608	–	–	﹤0.01%	1588
2014 Q2	$18K	Buy	+608	New	+$19.7K	﹤0.01%	1590

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nuveen's NAVB Position: Q2 2016 in Review

Nuveen sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 511 shares — an estimated $10 sold.

Nuveen first reported a position in NAVB in Q2 2014 and held it in 8 quarters. The position peaked at $23K in Q4 2014. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Nuveen reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Nuveen sold 511 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $10.
Nuveen first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2014 and held it in 8 quarters.
Nuveen's Navidea Biopharmaceuticals Inc. position peaked at $23K in Q4 2014.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Nuveen's 13F filing for Q2 2016, filed 12 Aug 2016.